Author:
Liu Chung-Heng,Habig Gregory,Smaltz Christa,Halegoua-DeMarzio Dina
Publisher
Springer Science and Business Media LLC
Reference93 articles.
1. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. https://doi.org/10.1038/nrgastro.2017.109.
2. Amiri Dash Atan N, Koushki M, Motedayen M, Dousti M, Sayehmiri F, Vafaee R, et al. Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2017;10(Suppl1):S1–7.
3. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37(Suppl 1):81–4. https://doi.org/10.1111/liv.13299.
4. Hong HC, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology. 2014;59(5):1772–8. https://doi.org/10.1002/hep.26716.
5. Choe EK, Kang HY, Park B, Yang JI, Kim JS. The association between nonalcoholic fatty liver disease and CT-measured skeletal muscle mass. J Clin Med. 2018;7(10). https://doi.org/10.3390/jcm7100310.